Delving into the Latest Updates on CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) with Synapse

Overview

Basic Info

Drug Type

CAR-NK

Synonyms

CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells

Target

CD70 x IL15R

Mechanism

CD70 inhibitors(CD70 antigen inhibitors), IL15R agonists(Interleukin-15 receptors agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [3]

Active Indication

Advanced Renal Cell CarcinomaMesotheliomaOsteosarcoma+ [3]

Inactive Indication-

Originator Organization

The University of Texas MD Anderson Cancer Center

Active Organization

The University of Texas MD Anderson Cancer Center

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.
Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.

Start Date01 Nov 2022

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)

Login to view more data

100 Translational Medicine associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)

Login to view more data

100 Patents (Medical) associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)

Login to view more data

100 Deals associated with CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Renal Cell Carcinoma	Phase 2	US	The University of Texas MD Anderson Cancer Center	29 Mar 2023
Mesothelioma	Phase 2	US	The University of Texas MD Anderson Cancer Center	29 Mar 2023
Osteosarcoma	Phase 2	US	The University of Texas MD Anderson Cancer Center	29 Mar 2023
Acute Myeloid Leukemia	Phase 2	US	The University of Texas MD Anderson Cancer Center	01 Nov 2022
B-Cell Lymphoma	Phase 2	US	The University of Texas MD Anderson Cancer Center	01 Nov 2022
Myelodysplastic Syndromes	Phase 2	US	The University of Texas MD Anderson Cancer Center	01 Nov 2022